Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

The 2022 plea by an HIV network NGO highlights gaps in procurement and quality of ARV therapy drugs; 16 states yet to file ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

China has announced a US$3.49 million (R60 million) partnership with South Africa to expand HIV prevention services among adolescents and young people, as ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Switching from etravirine- to doravirine-containing regimen maintains viral suppression in people with HIV-1 infection, including those with archived resistance to NNRTIs.